AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Policy

House Committee Subpoenas AbbVie Over Drug Pricing for Humira, Imbruvica

Shares of AbbVie fell nearly 4% Tuesday following the issuance of a subpoena from the U.S. House Oversight and Reform Committee regarding an ongoing investigation into drug pricing.

September 2, 2020

3 min read

Alex Keown

Business

AbbVie Taps Harvard University for Viral Infection Research Partnership

AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.

August 25, 2020

2 min read

Alex Keown

Business

AbbVie Expands Fibrotic Disease Partnership With Morphic Therapeutics

Under terms of the licensing deal, Morphic will receive an infusion of $20 million for the license fee along with potential future development milestone payments and royalties from the sales of any commercialized candidates.

August 25, 2020

2 min read

Alex Keown

BioCapital

Clinical Catch-Up: August 3-7

It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.

August 6, 2020

8 min read

Mark Terry

Policy

Biopharma Update on the Novel Coronavirus: August 3

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.

August 3, 2020

3 min read

BioSpace Editorial Staff

Drug Development

AbbVie Eyes Regulatory Approval for Atogepant After Positive Phase III Migraine Study

Atogepant, an oral CGRP receptor antagonist, is an experimental migraine treatment AbbVie gained through its acquisition of Allergan.

July 30, 2020

3 min read

Alex Keown

BioCapital

Clinical Catch-Up: July 20-24

It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.

July 24, 2020

8 min read

Mark Terry

Drug Development

AbbVie’s Rinvoq Hits the Mark in Pivotal Phase III Dermatitis Trial

AbbVie announced that its Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in the second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.

July 22, 2020

2 min read

Mark Terry

FDA

Allergan/AbbVie’s Macular Degeneration Drug Abicipar Pegol Rejected by FDA

The U.S. Food and Drug Administration issued a Complete Response Letter, a rejection, of Allergan’s Biologics License Application for Abicipar pegol for neovascular age-related macular degeneration.

June 26, 2020

3 min read

Mark Terry

JOBS